Although it has been acknowledged for quite some time that dynamic chromatin modifications may be an independent route to drug resistance in cancer cells and thus embodies a promising drug target in combination with various drugs including ICB, it was not until the recent FDA approval of tazemetostat (Trade name: Tazverik, developer: Epizyme), a first-in-class small molecule inhibitor of enhancer of zeste homolog 2 (EZH2), that this hypothesis has been feasible for clinical testing. This evidence concerns the gene EZH2 and cancer.